Taking aspirin for up to 6.5 years does not lower the risk of getting cancer or dying from cancer in people aged 70 and older, and any possible benefit would likely take more than 10 years to appear—longer than most people in this age group are expected to live.
Evidence from Studies
No evidence studies found yet.
What Would Prove This
Per GRADE and EBM methodology, here is what ideal scientific evidence would look like to definitively prove or disprove this claim, ordered from strongest to weakest.
A meta-analysis of RCTs with long-term follow-up (>10 years) assessing cancer incidence and mortality in elderly populations randomized to aspirin vs. placebo.
A systematic review and meta-analysis of RCTs enrolling adults aged 70+ without cancer, randomized to daily low-dose aspirin (81 mg) or placebo for at least 10 years, with primary endpoints of colorectal, lung, and overall cancer incidence and cancer-specific mortality, analyzed by intention-to-treat with subgroup analysis by baseline cancer risk.
A prospective cohort study can estimate the association between long-term aspirin use and cancer outcomes in elderly populations with sufficient follow-up.
A prospective cohort study following 10,000 adults aged 70–75 without cancer, stratified by aspirin use (≥5 years vs. never), with annual cancer screening, biopsy confirmation, and mortality tracking over 15 years, adjusting for smoking, BMI, and NSAID use.
A case-control study can assess whether prior aspirin use is less common among elderly individuals diagnosed with colorectal cancer compared to matched controls.
A matched case-control study comparing 1,500 elderly patients (≥70) diagnosed with colorectal cancer to 3,000 age- and sex-matched controls without cancer, assessing prior aspirin use (dose, duration, formulation) via pharmacy records and structured interviews.
A cross-sectional survey can estimate the prevalence of aspirin use among elderly cancer survivors versus non-cancer individuals.
A cross-sectional survey of 8,000 adults aged 70+ comparing aspirin use history between those with prior cancer diagnosis (n=2,000) and those without (n=6,000), using validated questionnaires and medical record verification.
An expert opinion can summarize hypotheses about aspirin’s anticancer effects but cannot provide empirical evidence.
A narrative review by oncology and geriatrics experts summarizing biological plausibility and observational data on aspirin and cancer, without original data analysis.